Targets › USES
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Neurology, Other; next expected readout Mar 2027.
Open in Phaseline: the race on USES, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| UMC Utrecht | Etidronate Bisphosphonate; inhibits mineralization by suppressing osteoclast activity and reducing bo | USES | Phase 3 | Pseudoxanthoma Elasticum; Fahr Disease | Mar 2027 |
Pseudoxanthoma Elasticum (1) Fahr Disease (1)
small molecule (1)
UMC Utrecht (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.